Left bundle branch pacing improves CRT response and reduces mortality in heart failure patientsLeft bundle branch pacing shows promise for heart failure patients

This meta-analysis synthesized data from 24 studies to evaluate the efficacy and safety of left bundle branch pacing (LBBP) compared to traditional biventricular pacing (BVP) in patients with heart failure undergoing cardiac resynchronization therapy. The total population analyzed consisted of 9,278 patients. The primary objective was to determine if LBBP provides superior electrical, structural, and clinical outcomes compared to the standard BVP approach.

The intervention of interest was left bundle branch pacing (LBBP), while the comparator was biventricular pacing (BVP). The study evaluated several key metrics including procedural metrics, electrical parameters, and clinical outcomes such as mortality and hospitalization rates. The meta-analysis included a mix of randomized controlled trials and cohort studies to provide a comprehensive overview of the current evidence base.

Regarding procedural and electrical outcomes, LBBP was associated with significantly reduced fluoroscopy time (MD -7.00; 95% CI -9.99 to -4.01) and reduced procedural duration (MD -23.62; 95% CI -35.29 to -11.95) compared to BVP. Electrical parameters also favored LBBP, showing a reduction in QRS duration (MD -17.11; 95% CI -21.02 to -13.20) and an increase in left ventricular ejection fraction (LVEF) (MD 3.58; 95% CI 2.95 to 4.22). Success rates for the procedure were reported as similar between the two groups.

Clinical outcomes showed a significant advantage for LBBP. The odds ratio for CRT response was 1.85 (95% CI 1.06 to 3.23), and the odds ratio for super-response was 1.56 (95% CI 1.38 to 1.77). Most notably, LBBP was associated with a lower rate of all-cause mortality (OR 0.57; 95% CI 0.48 to 0.68) and a lower rate of heart failure hospitalization (OR 0.50; 95% CI 0.43 to 0.57) compared to BVP.

Safety and tolerability findings indicated that LBBP and BVP have comparable safety profiles. No specific adverse event rates or discontinuation rates were reported to differentiate the two techniques. The results suggest that LBBP is a viable and potentially superior alternative to BVP for patients requiring cardiac resynchronization therapy.

These findings contribute to the understanding of heart failure management. While the meta-analysis suggests LBBP is superior in improving electrical, structural, and clinical outcomes, it is important to note that the superiority of LBBP is based on a meta-analysis of 24 studies. The inclusion of both RCTs and cohort studies may introduce variability in the strength of the evidence.

Methodological limitations were not specifically detailed, but the diversity of study designs (RCTs and cohort studies) suggests a need for cautious interpretation of the pooled effect sizes. Clinical implications suggest that LBBP may be a preferred option for improving outcomes in heart failure patients, but practitioners should consider the specific patient profile and the limitations of the pooled data. Questions remain regarding the long-term durability of LBBP leads and the specific factors that lead to a 'super-response' in the LBBP cohort.